<DOC>
	<DOC>NCT01520753</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to compare two different active treatment regimens of biphasic insulin aspart in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Type 2 diabetes Duration of diabetes for longer than 12 months Body mass index (BMI) below 35.0 kg/m^2 HbA1c below 11.0 % Treatment with BHI (biphasic human insulin) 20 or 30 twice daily for at least three months and in the last month as sole antidiabetic treatment (i.e., no additional oral hypoglycaemic medication or daily use of shortacting insulin supplement) Current treatment with agents affecting glucose metabolism History of drug or alcohol dependence Impaired hepatic function Impaired renal function Cardiac disease Proliferative retinopathy Recurrent severe hypoglycaemia or advanced neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>